不同门冬酰胺酶制剂对巴西儿童急性淋巴细胞白血病预后的影响:多中心回顾性对照研究
该多中心回顾性对照研究纳入419例首次治疗的儿童急性淋巴细胞白血病患者,比较接受Leuginase®(B组)与Aginasa®(A组)门冬酰胺酶制剂者的预后。
要点
- 接受Leuginase®的患儿3年OS和EFS显著低于接受Aginasa®者。
- 门冬酰胺酶制剂选择可能影响儿童ALL的长期生存结局。
- 临床应评估并监测门冬酰胺酶活性以确保疗效。
核心结论
- 儿童ALL患者接受不同门冬酰胺酶制剂对3年OS和EFS有影响,Leuginase®组预后较差。
研究设计与样本
- 多中心回顾性观察性研究,随后进行前瞻性随访。
- 纳入2014至2018年间10个转诊中心首次治疗的1至18岁儿童ALL患者419例,A组282例,B组137例。
临床怎么用
- 临床应评估并监测门冬酰胺酶活性,确保其达到治疗活性水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our group recently showed that the (ASNase) formulation available in Brazil from 2017 to 2018 when used at the same dose and frequency as the formulation provided previously did not reach the activity considered therapeutic. Based on these, our goal was to assess the impact of these facts on the prognosis of children with ALL at different oncology centers. A multicentre retrospective observational study followed by a prospective follow-up. Patients aged >1 and <18 years in first-line treatment followed up at 10 referral centres, between 2014 and 2018 who received the formulation Leuginase® were identified (Group B). For each patient, the centre registered 2 patients who received ASNase in the presentation of Aginasa® exclusively (Group A). Data collection was registered using (Redcap® ). A total of 419 patients were included; 282 in Group A and 137 in B. Group A had a 3-year OS and EFS of 91·8% and 84·8% respectively, while Group B had a 3-year OS of 83·8% (P = 0·003) and EFS of 76·1% (P = 0·008). There was an impact on 3-year OS and EFS of children who received a formulation. This result highlights the importance of evaluating ASNase and monitoring its activity.
引用
- Michalowski MB, Cecconello DK, Lins MM, et al. Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study. Br J Haematol. 2021. PMID: 33993488. doi:10.1111/bjh.17494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。